AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03506633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each subject in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured.
Study NCT02506621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECHNOMED pocket ECG
Study NCT03706352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunneling epidural catheter
Description: The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
Study NCT03706352 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tunneling epidural catheter
Description: The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
Study NCT00449969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zoll AED pro
Description: Arm one (Extended feedback) offers full feedback guidance during CPR
Study NCT00449969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zoll AED pro
Description: In arm two (limited feedback) feedback is modified lacking several elements of feedback
Study NCT00312962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT)
Description: TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
Study NCT00312962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer games
Description: The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
Study NCT04029038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Description: Given IV
Study NCT04029038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04029038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04348578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QMix 2in1
Description: In QMix 2in1 group root canals were irrigated with Mix as a final irrigation.
Study NCT01517776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
Study NCT01517776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
Study NCT03012945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia
Description: Combined epidural-general anesthesia and postoperative epidural analgesia. General anesthesia is performed as that in the general anesthesia group. Epidural anesthesia is performed with ropivacaine. Epidural analgesia is performed with a mixture of ropivacaine and sufentanil.
Study NCT03012945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia and postoperative intravenous analgesia. General anesthesia is performed with propofol induction and propofol and/or sevoflurane maintenance. Intravenous analgesia is performed with morphine.
Study NCT04088357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TolaSure Topical Gel
Description: TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
Study NCT04088357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vehicle Gel
Description: TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
Study NCT00268398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin, folinic acid, fluorouracil
Description: folinic acid 200 mg/m² (day 1\&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1\&2) continuous 5FU 600mg/m² (day 1 to 2)
Study NCT00268398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, irinotecan, folinic acid, fluorouracil
Description: FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)
Study NCT00504231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Influenza Vaccine (2007-2008)
Description: Manufactured by Sanofi Pasteur
Study NCT00504231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Influenza Vaccine (2007-2008)
Description: Manufactured by Sanofi Pasteur
Study NCT02506621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZIO xt patch
Study NCT02506621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoMe
Study NCT03746756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study.
Study NCT04484012 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Description: Given IV
Study NCT00836472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide/Metformin 5 mg/500 mg Tablets
Description: 1 x 5 mg/500 mg, single-dose fasting
Study NCT03746756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT+RMC-PC
Description: In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
Study NCT05800119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain-level condition
Description: Participants will receive a brief reading passage about the neurobiological effects of psychotherapy.
Study NCT00836472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucovance® 5 mg/500 mg Tablets
Description: 1 x 5 mg/500 mg, single-dose fasting
Study NCT04342663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.
Study NCT04342663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.
Study NCT02977221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
Study NCT01959204 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: Pain
Study NCT05249595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface electromypgraphy-based interface to predict human ankle joint motion intent and use in ankle assistive devices
Description: The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the sEMG signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
Study NCT05800119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mind-level condition
Description: Participants will receive an active control consisting of a brief reading passage about the effectiveness of psychotherapy.
Study NCT03314649 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Lavage of the Peritoneal Cavity
Study NCT00835484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir Capsules 300 mg
Description: 1 x 300 mg, single-dose fasting
Study NCT00835484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OMNICEF® 300 mg
Description: 1 x 300 mg, single-dose fasting
Study NCT01621282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: A 6-month interactive course on critical appraisal
Study NCT01621282 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Conventional
Description: Conventional method/no intervention
Study NCT02826304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy
Description: All the cases were performed by the same surgical team~1. Incision is made at the anterior cervical lip below the bladder reflection~2. Anterior peritoneal entry .~3. Douglas pouch entry.~4. The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~5. Uterine artery clamping division and ligation~6. After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~7. Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~8. Hemostasis~9. The vaginal vault is closed after insertion of intraperitoneal drain and
Study NCT02826304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic assisted vaginal hysterectomy
Description: 1. Uterine manipulator was inserted through the cervix to mobilize the uterus~2. Veress needle was inserted through the base of the umbilicus~3. creation of pneumoperitoneum~4. Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~5. The round and the utero-ovarian ligament are coagulated and divided.~6. Dissection through the vesico-uterine space to displace bladder away from the cervix.~7. Uterine artery was coagulated and divided laparoscopically~8. anterior colpotomy over the cup of the uterine elevator.~9. Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis.
Study NCT02999893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
Study NCT01591161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: 1 drop of study medication into the study eye QID for 14 days
Study NCT01591161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 drop of vehicle into the study eye QID for 14 days.
Study NCT05278923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SALAD simulation device
Description: An airway CPR manikin was modified to simulate regurgitation during CPR . A manual pump was fixed on the bottom of the torso to simulate the stomach. A clear vinyl tube was connected the manikin's oesophagus and the outflow port of the pump. A water container outside the manikin was filled with simulated gastric content and connected to the inflow port of the pump through another vinyl tube. The manikin's left main bronchus was occluded using a red cap provided by the manufacturer. The lung was simulated by an anaesthesia breathing bag placed outside the manikin and connected to the manikin's right main bronchus via a breathing circuit. A compression pad was attached to the bottom of the manikin's compression plate. During chest compression, the compression pad squeezed the pump to regurgitate gastric contents into the oropharynx
Study NCT04225715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide (NUC)
Description: Nucleos(t)ide (NUC) will be administered orally
Study NCT04225715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleos(t)ide (NUC)
Description: Nucleos(t)ide (NUC) will be administered orally
Study NCT04225715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpAM (RO7049389)
Description: CpAM (RO7049389) will be administered orally
Study NCT04225715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR7 (RO7020531)
Description: TLR7 (RO7020531) will be administered orally
Study NCT04225715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: siRNA (RO7445482)
Description: siRNA (RO7445482) will be administered subcutaneously
Study NCT04225715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN
Description: PEG-IFN will be administered subcutaneously
Study NCT04225715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 LNA (RO7191863)
Description: PD-L1 LNA (RO7191863) will be administered subcutaneously
Study NCT03931616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STEMO
Description: STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
Study NCT03931616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
Study NCT01510938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. acidophilus DDS-1, B. lactis UABLA-12
Description: 1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
Study NCT01510938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
Study NCT02805764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Homeoblock
Description: A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
Study NCT04149691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL304110
Description: CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
Study NCT03639181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB226
Description: 3mg/kg treat every 2 weeks
Study NCT03928704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT03928704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT03928704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
Study NCT03526432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
Study NCT00755677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulses
Description: subjects consume 1 pulse food daily for eight weeks
Study NCT02616484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichloroacetate (DCA)
Description: Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr.
Study NCT00868660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZP1848
Description: sc. bolus
Study NCT00868660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP1848
Description: sc. bolus
Study NCT02616484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dichloroacetate (DCA)
Description: Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr.
Study NCT02616484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
Study NCT02616484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
Study NCT02616484 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype
Description: Participants will be genotyped to determine GSTZ1 haplotype status.
Study NCT02616484 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Genotype
Description: Participants will be genotyped to determine GSTZ1 haplotype status.
Study NCT05249595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging-based interface to predict human ankle joint motion intent and use in ankle assistive devices
Description: The study involves the validation of computer algorithms to estimate human ankle joint motion intent and control of ankle joint assistance by using either a powered exoskeleton or an FES system. The ankle joint motions will include seated posture tasks and walking tasks. The instrumented treadmill and Vicon motion capture system will be used to facilitate the cyclic walking pattern and record the participant's kinematics. The human ankle joint volitional effort will be predicted by the ultrasound imaging signals from shank muscles. The powered exoskeleton or FES system will provide ankle joint assistance based on an assist-as-needed strategy.
Study NCT05557383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use peanut ball
Description: The peanut ball was placed between the legs of a woman in the intervention group immediately after she received her epidural and consented to participate in the study.
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir/3TC
Description: MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV/TDF/FTC
Description: standard combination therapy
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV/r + TDF/FTC or DRV/r + TDF/FTC
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV plus ABC/3TC or RPV/TDF/FTC
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV/r plus ABC/3TC
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC
Study NCT02284035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAL plus ABC/3TC
Study NCT01867073 — intervention group
Intervention type: OTHER
Intervention: Biomarker
Study NCT03941730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy